DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Endroit courant :
>
>
> This Story

Forward Printable StoryPrint Comment

 

 

Oncology Homepage

Study reports reduction in biopsy procedures performed when Prostate Health Index (phi) testing is used in clinical practice

Varian announces opening of new facility in Brazil

First patient treated with RayPilot in Turkey

Varian Halcyon treatment system receives Shonin approval

Baptist Hospital's Miami Cancer Institute awarded cancer research and education grant by IBA

ASCO expands TAPUR study enrollment after promising initial treatment outcomes seen

Delta4 Discover transmission detector approved for use by Varian Medical Systems on TrueBeam and Clinac systems

Intraoperative imaging systems market to reach $3.4 billion by 2024

Varian to showcase technologies for enhancing oncology care coordination at AONN+ Conference

United States proton therapy market is expected to reach nearly $1 billion, potentially $7 billion by 2025

New interim results support Imagio Opto-Acoustic (OA) breast imaging system's potential to reduce negative biopsies

Press releases may be edited for formatting or style
SAN ANTONIO, Sept. 24, 2016 /PRNewswire/ -- Seno Medical Instruments, Inc. (Seno Medical), the company pioneering the development of opto-acoustic technology as a tool to improve the process of diagnosing breast cancer, announced today interim results from the company's multicenter, European MAESTRO post-market surveillance and clinical follow-up study. The results demonstrate the potential of its Imagio® opto-acoustic (OA) breast imaging system to provide physicians with vital information needed to determine whether or not a suspicious mass is cancerous, with the goal of reducing the rate of negative biopsies. The data were presented at a clinical symposium at the Annual Scientific Meeting of the European Society of Breast Imaging (EUSOBI), the second largest conference in the world dedicated to breast cancer imaging, on September 24, 2016 in Paris.

"The interim results from MAESTRO add to the growing body of clinical evidence showing that the Imagio opto-acoustic diagnostic tool increases physicians' confidence when differentiating and classifying malignant and benign breast tissue," said the study's principal investigator Ruud Pijnappel, MD, PhD, Radiologist, University Medical Center, Utrecht, NL, who presented the interim analysis. "The improved accuracy that is possible with this technology could help women avoid painful biopsy procedures that sometimes follow false-positive diagnoses."

Story Continues Below Advertisement

EXPERIENCE THE DIFFERENCE

NEW CXDI-710C and CXDI-810C Wireless Digital Radiography Systems. NEW CXDI Control Software NE Version 2.16 for Windows® 7 and 10. Click for more information>>>



There are over 1.6 million biopsies performed annually1 and recent reported data noted an 81% "false positive" rate of biopsy procedures – the portion of biopsies that do not lead to breast cancer surgery.2 Seno Medical's Imagio breast imaging system, which received its CE Mark in 2014, has the potential to reduce negative biopsies by 43%. Seno Medical is targeting their PMA submission for the Imagio system to the U.S Food and Drug Administration by the end of 2016.

MAESTRO, a controlled, multi-center, observational, post-market surveillance and clinical follow-up study, was designed to assess the diagnostic value (specificity and sensitivity) of Opto-Acoustics to conventional diagnostic ultrasound (CDU) in suspicious masses classified as BI-RADS 4a and 4b. Investigators first performed CDU to reach a diagnosis and decision to biopsy followed by an Imagio OA examination. Two hundred female subjects with undiagnosed suspicious masses enrolled in the study.

The interim analysis of 78 subjects found that following the use of Imagio system, radiologists downgraded BI-RADS categories of the internal ultrasound control-classified BI-RADS 4a masses to BI-RADS 3 or 2 in 75% of cases, and BI-RADS 4b masses to either BI-RADS 3 or 2 in 37.5% of cases. The interim results also showed that Imagio OA also increased specificity to over 43%, with no significant loss in sensitivity. Importantly, clinicians were able to reduce the rate of false-positive diagnoses by 20% for the last 48 subjects evaluated in the study.
  Pages: 1 - 2 - 3 >>

Oncology Homepage


You Must Be Logged In To Post A Comment

Publicité
Développez la notoriété de votre marque
Enchères + Ventes Privées
Obtenir le meilleur prix
Acheter des équipement / pièces
Trouver le meilleur prix
Infos du jour
Lire Les dernières nouvelles
Annuaire
Consulter tous les utilisateurs DOTmed
Éthique concernant DOTmed
Voir notre programme d'éthique
L'or partie le programme de fournisseur
Recevoir des demandes PH
Programme de marchand de service d'or
Recevoir des demandes
Fournisseurs de soins de santé
Voir tous les outils des HCP (abréviation pour les professionnels de la santé)
Les travaux/Formation
Trouver / combler un poste
Parts Hunter +EasyPay
Obtenir des devis de pièces
Certification Récentes
Voir les utilisateurs récemment certifiés
Evaluation Récentes
Voir les utilisateurs récemment certifiés
Central de location
Louer de l’équipement à moindre prix
Vendre des équipements / pièces
Obtenir le maximum d'argent
Service le forum de techniciens
Trouver de l'aide et des conseils
Simple demande de propositions
Obtenir des devis pour des appareils
Expo Virtuelle
Trouver des services d'appareils
L'Access et l'utilisation de cet emplacement est sujet aux modalités et aux conditions du notre de nos MENTIONS LEGALES & DONNEES PERSONELLES
Propriété de et classe des propriétaires DOTmedà .com, inc. Copyright ©2001-2017 DOTmed.com, Inc.
TOUS DROITS RÉSERVÉS